Carrick Therapeutics Lays Foundation For 'Leading Oncology Business'

Carrick Therapeutics Ltd., a newly formed company focused on cancer drug development, will use the majority of a recent $95m financing to advance first-in-class molecules into the clinic and to progress other in-house, clinical-stage cancer therapy candidates.

Carrick's CEO Elaine Sullivan told Scrip the company is still in stealth mode and hasn't yet provided details about its portfolio assets but said the compounds the company has in development are targeting "the most aggressive cancers" such as colon, ovarian and breast cancer